• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Canopus BioPharma Reports Positive Results From Cancer Vaccine Study

Posted on: Tuesday, 4 November 2008, 12:00 CST

Canopus BioPharma, a developer of pharmaceutical technologies to help combat international health threats, has successfully completed the second phase of its cancer vaccine development.

The specialized laboratory study was analyzed at the Southern Research Institute in Birmingham, Alabama. The study used the blood of healthy human volunteers, vaccinated with Canopus Biopharma's cancer vaccine peptides, which then demonstrated anticancer properties against a panel of 12 human cancer cell lines in tissue culture.

For the first time, successful human testing confirms that Canopus BioPharma's proprietary, patented use of these cancer-targeted peptide antigens is effective as a vaccine against human cancer cells.

When used as a vaccine in healthy volunteers, the peptide antigens generate antibodies that are non-toxic to normal cells, but significantly effective in destroying human cancer cells in-vitro. In effect, the peptide antigens work by stimulating a person's own immune system, to protect the individual from developing certain forms of cancer.

Elizabeth Shanahan-Prendergast, president of oncology at Canopus BioPharma, said: "Successful results from this series of laboratory tests, using vaccinated, healthy volunteers, confirms proof of principle in humans. In the laboratory, the vaccinated human blood demonstrated that it can significantly inhibit the growth of a broad range of human cancer cells - including colorectal, prostate, small-cell lung, pancreatic, ovarian and breast - when compared to a control sample of non-vaccinated human blood."

Source: Datamonitor

More News in this Category